Actimed Therapeutics secures £3.7m for muscle-wasting disorder treatments

Actimed Therapeutics develops innovative pharmaceutical therapies for cancer cachexia and other muscle-wasting disorders, targeting patients affected by these conditions. The Ascot-based biotechnology firm recently secured £3.7m in new funding, resulting in an estimated post-money valuation of £86.2m.

Founded in 2016, the company maintains an online presence at http://www.actimedtherapeutics.com. Financial statements for the year ending 31 December 2025 reported a loss of £6.4m. The business has raised £3m so far in 2026, following £7.2m raised during the previous calendar year.

Staffing levels vary across sources, with official accounts listing 9 employees while LinkedIn data indicates a team of 14 people within the pharmaceutical manufacturing industry. Sven Anders Ullman was appointed as a director in July. LinkedIn profiles suggest he may be a qualified sales consultant for mobile capital goods at Gottfried Schultz Automobilhandels SE. Formal documentation for the share issuance was filed and allotted in June.